ArticleOncotarget2015

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.

Andreas Seeber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.